Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sino Biopharmaceutical ( (HK:1177) ) has shared an update.
Sino Biopharmaceutical Limited announced that its innovative drug, LM-350 ‘CDH17 ADC’, has received clinical trial approval from China’s National Medical Products Administration. This approval marks a significant step in addressing unmet clinical needs in treating gastrointestinal tumors, as LM-350 has shown strong anti-tumor activity, particularly in colorectal cancer models. The company aims to accelerate clinical research in China, following previous approvals from the FDA and patient enrollment in Australia.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the biopharmaceutical industry. It develops innovative drugs, with a particular emphasis on antibody-drug conjugates (ADCs) through its subsidiary, LaNova Medicines Limited.
Average Trading Volume: 124,297,514
Technical Sentiment Signal: Buy
Current Market Cap: HK$131.3B
For an in-depth examination of 1177 stock, go to TipRanks’ Overview page.